Saxagliptin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Saxagliptin
Saxagliptin: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Saxagliptin, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 7 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| diabetes | licence in another country |
| diabetes mellitus | licence in another country |
| diabetes mellitus, type 2 | licence in another country |
| glucose metabolism disorders | licence in another country |
| metabolic diseases | licence in another country |
| nutritional and metabolic diseases | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| type 2 diabetes mellitus |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10128C | Onglyza | Tablet 2.5 mg (as hydrochloride) | Valid |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 entries; 20 are shown in the data compiled for this report. Most are rated Moderate, and a few are Minor. Examples include:
- Moderate: phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol, nifedipine, hydrochlorothiazide, acetazolamide, amiodarone, benazepril, estradiol, ethinylestradiol, levonorgestrel, hydrocortisone, alpelisib, amobarbital, ethanol, abametapir (topical)
- Minor: topical hydrocortisone, topical alclometasone
- Knowledge-graph contraindication signals (model-derived, not label text): kidney disease, liver disease, gallbladder disease, pituitary hormone deficiency conditions, hypogonadotropic hypogonadism, Kallmann syndrome, adrenocortical insufficiency, Addison disease, thymus gland disease, infectious disease and substance abuse/dependence. These must be verified against the approved label.
Please refer to the TGA-approved Product Information (PI) for confirmed warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.